Sodium deoxyribonucleate (Derinat) intramuscular 1.5% 5 ml – [5 ampoules]

Description

Derinat Pharmacodynamics
The drug activates the processes of cellular and humoral immunity. Immunomodulatory effect is due to stimulation of B-lymphocytes, activation of T-helpers. Derinat® activates nonspecific resistance of the body, optimizing inflammatory reactions and immune response to bacterial, viral and fungal antigens. Stimulates reparative and regenerative processes. Increases the body’s resistance to infections, regulates hematopoiesis (helps normalize the number of leukocytes, lymphocytes, granulocytes, phagocytes, platelets). Derinat® has a pronounced lymphotropism and stimulates the drainage and detoxification function of the lymphatic system. Derinat® significantly reduces the sensitivity of cells to the damaging effects of chemotherapeutic drugs and radiation therapy. The drug has no embryotoxic, teratogenic and carcinogenic effects.

Indications
– Radiation injuries;
– hematopoiesis disorders;
– Myelodepression and resistance to cytostatics in cancer patients developed against the background of cytostatic and/or radiation therapy (stabilization of hematopoiesis, reduction of cardio- and myelotoxicity of chemotherapy);
– Stomatitis, induced by cytostatic therapy;
– Peptic ulcer, erosive gastroduodenitis;
– coronary heart disease;
– Obliterating vascular disease of the lower extremities, chronic coronary disease of the lower extremities stage II-III;
– Trophic ulcers, wounds that do not heal for a long time;
– odontogenic sepsis, purulent-septic complications;
– rheumatoid arthritis;
– burn disease;
– Preoperative and postoperative periods (in surgical practice);
– Endometritis, salpingo-oophoritis, endometriosis, myomas;
– Chlamydia, ureaplasmosis, mycoplasmosis;
– Prostatitis, benign prostatic hyperplasia;
– Chronic obstructive pulmonary diseases;
– pulmonary tuberculosis, inflammatory diseases of the respiratory tract.

Contraindications .
Individual intolerance.
Pregnancy and lactation:
It is necessary to consult a physician.
If it is necessary to prescribe the drug during pregnancy, the expected benefits to the mother and the potential risk to the fetus should be assessed.
During lactation, use strictly as directed by the physician.

Dosage and administration method

• Adults: intramuscularly for 1-2 minutes in 5 ml of 1.5% (75 mg) solution, at intervals of 24-72 hours.
• For ischemic heart disease: 10 injections at intervals of 48-72 hours.
• For peptic ulcer disease of the stomach and duodenum 5 injections at intervals of 48 hours.
• In cases of oncological diseases: 3 to 10 injections with an interval of 24-72 hours.
• In gynecology (endometritis, chlamydia, ureaplasmosis, mycoplasmosis, salpingo-oophoritis, myomas, endometriosis) – 10 injections at an interval of 24-48 hours.
• In andrology (prostatitis, benign prostatic hyperplasia) – 10 injections at intervals of 24-48 hours.
• In pulmonary tuberculosis – 10-15 injections at intervals of 24-48 hours.
• For acute inflammatory diseases – 3-5 injections at 24-72 hour intervals.
• In chronic inflammatory diseases – 5 injections at 24-hour intervals, then 5 injections at 72-hour intervals.
• If using 1.5% solution in 2 ml, intramuscular injections should be given daily with recalculation until the course dose of 375-750 mg is reached.
• In children the drug is administered intramuscularly according to the same scheme as in adults. A single dose of 7.5 mg (0.5 ml) is prescribed for children under 2 years of age.
• For children aged 2 to 10 years a single dose is determined at the rate of 0.5 ml of the drug per one year of life. From 10 years of age, the single dose is 5 ml of 1.5% solution, the course dose is up to 5 injections (15 mg/ml) of the drug.